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ABSTRACT
Dupuytren contracture is benign fibromatosis of the palmar and digital fascia of the hand. The presentation 
of the disease is progressive flexion contraction of the digits and impaired function of the hand. The dis-
ease is common primarily in north Europe and it is found in Bulgaria as well. Dupuytren’s disease is known 
in the literature since1614, but there are still unsolved problems. Etiology and pathogenesis is unknown and 
there are many hypotheses of related exogenous and endogenous factors. Multiple treatment options, in-
cluding surgery and medical procedures, have been suggested but there is not yet an effective one. 
MATERIAL AND METHODS:  In this survey we represent review of the new concepts of management and 
treatment of Dupuytren contracture. The most recent treatments used are extensive percutaneous aponeu-
rotomy and lipografting, injecting Clostridium histolyticum collagenase, shockwave therapy and radio-
therapy. 
RESULTS AND CoNCLUSIoN: Each of the treatment options has certain advantages and disadvantag-
es and further investigations are required for better outcomes.
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INTRoDUCTIoN
The digitopalmar contracture named after 
Dupuytren (1831), is a fibrous, proliferative 
hyperplasia of the pre- existing connective tissue 
structures of the fascia of the fingers and palm (1). 
It is a common disorder and affects 30 million peo-
ple worldwide. The economic consequence of the im-
paired hand function leads to disability and affects 
the patient’s work life. They are faced with difficul-
ties every day in their personal life- washing face and 
putting hand in pockets.
MATERIAL AND METHoDS
The goal of this article is to make a review of the 
recent advances in treatment of Dupuytren’s disease 
including surgical and nonsurgical treatments. We 
performed retrospective literature review and we used 
the key words “Dupuytren contracture, needle apo-
neurotomy, advances, treatment, assessment surgical 
treatment, nonsurgical treatment, radiotherapy”. Ar-
ticles, which we include was written only in English.
RESULTS
The incidence of the Dupuytren’s disease in the 
population is variable according to age, sex and eth-
nicity.  It affects male gender predominantly in coun-
tries of northern Europe and Scandinavia. It is rare 
in dark colored skin individuals. According to Mik-
kelsen in a study of Norwegian population includ-
ing 15 950 persons, contracture is registered in 10,5% 
of males and 3,1 of females (2). Burge consider that 
Dupytren contracture is genetic inherited disorder of 
the connective tissue in 30%. It is common in Ger-
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many, Russia, Great Britain. Although uncommon in 
most of Asia, Japan and Taiwan, have higher preva-
lence, comparable to the values reported in Northern 
European population. These patients present with 
less severe form of the disease, where only nodules 
are present, without formation of pathological cords.
(3)
Dupuytren’s disease affects both age and sex. 
Men are predominantly affected by the disease than 
women in 9:1, 6:1 ratio according to different sourc-
es (4). The disease has been reported in infants and 
children but there have been only a few articles up to 
now. The incidence is higher for men at the age of 50 
and for women the 6th decade. By the ninth decade 
the prevalence across gender is equal (5). The recur-
rence rate is equal in both sexes. Bilateral disease is 
more common in men at 59 % versus 43% of wom-
en (6).
The etiology of the disorder remains unclear. As-
sociation between exogenous and endogenous factors 
has been researched. The disease is thought to be an 
autosomal dominant inheritance with variable pene-
trance (7). Heredity is the most plausible hypothesis 
and no gene has been defined yet. Certain predispo-
sition exist, which under the influence of number of 
factors could occur in pathological condition. Studies 
have found that there is increased risk for Dupuytrens 
contracture in patients with underlying health con-
ditions, such as diabetes mellitus and epilepsy. The 
higher prevalence is often believed to be related to the 
microangiopathy and increased collagen production 
(8). These patients also have increased rates of flexor 
tenosynovitis and carpal tunnel syndrome and other 
proliferative disorders in the hand. Arafa studied the 
association between epilepsy and Dupuytren contrac-
ture and has found prevalence similar to the general 
population (9). 
Association between Dupuytren’s disease and 
exogenous factors such as smoking, alcochol con-
sumption and manual labor is controversial. Studies 
of Burke and Goldtfredsen present higher incidence 
of the disease among smokers and alcocholics, and 
worse presentation as well (10,11). Others point that 
there are considerable group of patients suffering 
from this condition who have never smoked or drank 
alcohol (12). One statistical finding that should not 
be underestimated is that 42% of people with severe 
Dupuytren contracture died of cancer. It is evident 
that more investigation is needed to confirm what 
can be the cause of the disease (12,13). 
The disease process is similar to wound healing 
which involves the proliferation of fibroblasts depo-
sition of collagen, myofibroblast contraction, growth 
factors  such as transforming growth factor β (TGF 
β) (14). Researchers found similarities between the 
presenting features of neoplastic process and Du-
puytren’s disease because of the high recurrence rate 
(14,15,16). The course of the disease includes three 
stages and it is described by Luck in 1959- prolifer-
ative, involutional and residual stage. At first, only 
nodules are present at the base of the fingers and 
the skin of the distal palmar crease. In the involu-
tional and residual stage the normal palmar fascia is 
changed into pathological fibrous cords and progres-
sive digital flexion deformity occur. The palmar skin 
and underlying tissue thicken, the subcutaneous fat 
becomes fibrotic leading to attachment of the skin to 
the underlying fascial structures (16) (Fig.1), (Fig. 2).
Dupuytren’s disease may have a range of 
presentations especially in patients with strong 
diathesis. Ectopic disease can be either regional or 
Fig. 1. Dupuytren disease in a male patient
Fig. 2. Lederhose disease 
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distant ectopic disease. Regional presentation include 
Garrod’s nodes (dorsal Dupuytren’s nodule). These 
are fibrous lesions of the skin over the proximal in-
terphalangeal joint and usually are associated with 
bilateral disease. Distant ectopic disease is found in 
patients with strong diathesis. Lesions of the plantar 
fascia is Lederhose disease (Fig. 3) (17) and lesions of 
corpus cavernosum is Peyronie’s disease (18). 
Surgical treatment
Treatment of Duputren’s disease is a matter of 
discussion, there are surgical and nonsurgical treat-
ment options.  Historically surgery has been “the 
gold standard”, and limited fascectomy is the most 
frequently practiced procedure.
The indications for surgical treatment are 
metacarpophalangeal (MP) joint contracture of 30 
degrees or greater, or proximal inerphalangeal( PIP) 
joint contracture of 20 degrees or greater with docu-
mented progression (19). The Hueston table top test 
is positive and contracture of this degree begins to 
cause functional complains such as difficulties in 
washing face or putting hands in pockets.
Surgical treatment options include open fasciot-
omy (20), closed fasciotomy (21), limited fascectomy, 
percutaneous needle aponeurotomy (PNA) (22,23,24 
and enzyme fasciotomy (19,25,26). Surgical interven-
tion does not cure Dupuytren’s disease. The aim of 
the surgical technique is contracture correction and 
improvement of the function of the hand (19). Before 
perform any type of surgery procedure, the patient 
must be informed for the type of the procedure, ad-
vantages and possible complications.
Limited fasciectomy is the most frequently 
practiced treatment for the Dupuytren contracture. 
The treatment should be performed before contrac-
ture of 60° has developed, because of the possible 
joint contracture (27). All incisions must follow the 
basic hand surgery principles. No incision should 
cross a flexion crease under right angle. Using Brun-
ner zigzag incisions the cord is dissected and path-
ological changed tissue, cords and nodules are ex-
cised. The wound is closed and if needed Z-plasty is 
performed. Mini-chevron incision is a new approach 
suggested by Papaloїzos. The idea of a new design of 
zigzag flaps as short as 4-5 mm with better preserved 
blood supply. Usually, one incision should be made 
for each affected ray or finger (18). Even the surgery 
is “the gold standard”, it has been found a high num-
ber of complications associated with it. They are di-
vided in two groups – intraoperative and postopera-
tive. The most common intraoperative complication 
is digital nerve injury reported as 3,4% in 15 stud-
ies reviewed. Postoperative complications include 
skin necrosis, infection, pain in the scar site. Patients 
report of joint stiffness and reduced flexion ability 
compared to their pre- operative state (28). 
Fig. 3.Progression of the disease
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Dermofasciectomy is a surgical method where 
the diseased fascia and the overlying skin are excised. 
The defect of the skin is covered by a skin graft. It 
is proposed by Hueston (29) in 1961 but it has nev-
er been popular. In a study of 143 digits the risk of 
recurrence was only in 12 rays -8,4% of rays, 11,6% 
of  patients (30).  Even that excisional surgery is es-
tablished as standard treatment for the Dupuytren’s 
contracture, the drawback is the long postoperative 
recovery period and high number of complications.
Percutaneous needle aponeurotomy or fascioto-
my is the first ever used method of treatment for the 
contracture. It is developed by Henry Cline in 1777 
in London and later modified by Lermisiaux. Stan-
dard technique of needle aponeurotomy according to 
Lermisiaux is performed under local anesthesia. Us-
ing a 16 G injection needle the affected cords are cut 
and the full extension of digits is restored (31) (Fig. 
4), (Fig. 5). 
The technique is minimally invasive with short 
recovery period and the results compared to limited 
fasciotomy are similar. Disadvantage is reported in 
randomized controlled study which shows high re-
currence rate of 64% (18,32).
Hovius et al. suggested combine fat grafting 
with a novel minimally invasive percutaneous re-
lease. In this procedure the fat graft is interposed in 
the space between the released cord and the underly-
ing skin (33). It is reported that interposed graft pre-
vent recurrence (34). The results are promising but 
further investigations are needed.
Nonsurgical treatment
Because of the complications described in the 
literature the need for less invasive methods uncov-
er new possibilities. A great number of treatment op-
tions have been found as alternatives for surgery- ad-
ministration of steroids (35,36), vitamin E, dimeth-
yl sulfoxid, radiotherapy, ultrasonic therapy, hand 
therapy (37,38), enzymatic fasciotomy (39), collage-
nase (25,40,41).
Injectable Clostridial collagenase has gain pop-
ularity in the last few years. It is known as xiaflex and 
also xiapex in Europe. This treatment is approved 
in USA and in some countries in Europe. The col-
lagenase clostridium hystoliticum consists of multi-
ple collagenase subtypes. The collagenase enzym is 
injected into the cord where it disrupts the collagen 
bands (19). Several studies have been published un-
til now. Overall, it can be concluded that the effica-
cy, safety, and complication profiles of CHCs appear 
to compare favorably with the current surgical tech-
niques in adult patients with a palpable DD cord (25).
Tomasek et al., have investigated the effect of 
INF-gamma on myofibroblast and came to the con-
clusion that INF-gamma is able to suppress the dif-
ferentiation of myofibroblasts and thus the contrac-
tile force is being reduced as well (12,42).
Knobloch et al, conducted a randomized-con-
trolled study using focused extracorporeal shock 
waves in the treatment of in Peyronie’s disease. Re-
sults were promising, the pain was reduced and qual-
ity of life improved. The hypothesis is that focused 
extracorporeal shock wave therapy can be used as a 
non-invasive tool to decrease the force of contracture 
and reduce the fibromatosis of the palm (12,43). 
In a follow-up of 13 years radiotherapy has 
proved to be effective in prevention the disease 
progression in early-stage Dupuytren’s contracture 
- 59% remained stable, 10% improved and 31% - 
progressed (44).
Fig. 4. Needle aponeurotomy
Fig. 5. Needle aponeurotomy - immediate result.
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CoNCLUSIoN
Dupuytren’s disease is a common fibroprolif-
erative disorder with unknown etiology. Up to now 
there are many hypotheses but not a clear answer. 
The first description of the contracture found in the 
literature was proposed by Cline and he suggested a 
surgical method for the disease in 1778 (18). Since 
then, there are a numerous techniques and meth-
ods in the management of Dupuytren’s disese. Each 
of them has its own advantages and disadvantages. 
Still, there is no clear indication which technique is 
appropriate for treatment an exact patient or a group 
of patients. Decision is made of the surgeon, which 
one he should prefer. Minimally invasive needle apo-
neurotomy has fast recovery and good first results 
but considerable high recurrence rate. Radical exci-
sional surgery such as dermofasciectomy shows the 
opposite: low recurrence rate but high level of com-
plication rate. Non operative techniques in example 
studies of clostridial collagenase report promising re-
sult, but it is expensive treatment. Among the most 
recent treatment options are multi-needle aponeu-
rotomy, extensive percutaneous aponeurotomy and 
lipografting, injecting collagenase Clostridium his-
tolyticum, INF-gamma and shockwave therapy. Fur-
ther investigation should be made in order to fill in 
the gaps in the knowledge and concept of Dupuy-
tren’s disease.
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